ARTICLE | Emerging Company Profile
Epsilogen: co-opting IgE antibodies against cancer
Epsilogen leverages natural high affinity of IgE for immune cells to target solid tumors
June 5, 2020 8:38 PM UTC
Epsilogen is taking a long overlooked isotype of human antibodies -- the IgE class -- and leveraging their high affinity for immune effector cells to seek out and destroy solid tumors.
“What we are doing is we are redirecting the tropism of a major arm of the immune system,” CEO Tim Wilson told BioCentury...